Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy

Annals of Oncology

Volumn 27, Issue 12, 2016, Pages 2288-2294

  Ahmed, K A ^a   Abuodeh, Y A ^a   Echevarria, M I ^a   Arrington, J A ^b   Stallworth, D G ^b   Hogue, C ^c   Naghavi, A O ^a   Kim, S ^a   Kim, Y ^b   Patel, B G ^d   Sarangkasiri, S ^a   Johnstone, P A S ^a   Sahebjam, S ^b   Khushalani, N I ^b   Forsyth, P A ^b   Harrison, L B ^a   Yu, M ^a   Etame, A B ^b   Caudell, J J ^a  

^a Department of Radiation Oncology ^*

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c University of Louisville School of Medicine   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

anti PD 1 therapy; brain metastases; melanoma; stereotactic radiation

Indexed keywords

ACRYLONITRILE; ANILINE DERIVATIVE; B RAF KINASE; BRAF PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MEK INHIBITOR I; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; MALE; MELANOMA; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RADIOSURGERY; SECONDARY; VERY ELDERLY;

ACRYLONITRILE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS B-RAF; RADIOSURGERY;

EID: 85015886842     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw417     Document Type: Article

References (24)

1. Davies, M.A., Liu, P., McIntyre, S., et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117 (2011), 1687–1696.
2. Sperduto, P.W., Chao, S.T., Sneed, P.K., et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77 (2010), 655–661.
3. Weber, J.S., D'Angelo, S.P., Minor, D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16 (2015), 375–384.
4. Long, G.V., Stroyakovskiy, D., Gogas, H., et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386 (2015), 444–451.
5. Long, G.V., Trefzer, U., Davies, M.A., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13 (2012), 1087–1095.
6. Margolin, K., Ernstoff, M.S., Hamid, O., et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13 (2012), 459–465.
7. Kefford GMR, M.M., Arance, A., Nathan, P., et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open‐label, single‐arm, phase 2, multicenter study. Pigment Cell Melanoma Res, 26, 2013, 965.
8. Kiess, A.P., Wolchok, J.D., Barker, C.A., et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92 (2015), 368–375.
9. Mathew, M., Tam, M., Ott, P.A., et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 23 (2013), 191–195.
10. Ahmed, K.A., Freilich, J.M., Sloot, S., et al. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol 122 (2015), 121–126.
11. Ahmed, K.A., Stallworth, D.G., Kim, Y., et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 27 (2016), 434–441.
12. Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
13. Patel, B.G., Ahmed, K.A., Johnstone, P.A., et al. Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma Res 26 (2016), 382–386.
14. Lin, N.U., Lee, E.Q., Aoyama, H., et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16 (2015), e270–e278.
15. Chang, J., Atkinson, H., A'Hern, R., et al. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. Eur J Cancer 30A (1994), 2093–2095.
16. Agarwala, S.S., Kirkwood, J.M., Gore, M., et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22 (2004), 2101–2107.
17. Topalian, S.L., Sznol, M., McDermott, D.F., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32 (2014), 1020–1030.
18. Robert, C., Karaszewska, B., Schachter, J., et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372 (2015), 30–39.
19. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
20. Berghoff, A.S., Ricken, G., Widhalm, G., et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology 66 (2015), 289–299.
21. Gaudy-Marqueste, C., Carron, R., Delsanti, C., et al. On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Ann Oncol 25 (2014), 2086–2091.
22. Narayana, A., Mathew, M., Tam, M., et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113 (2013), 411–416.
23. Fontanella, A.N., Boss, M.K., Hadsell, M., et al. Effects of high-dose microbeam irradiation on tumor microvascular function and angiogenesis. Radiat Res 183 (2015), 147–158.
24. Yu, C., Chen, J.C., Apuzzo, M.L., et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 52 (2002), 1277–1287.